1 search result for:

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with lead molecule EP395. EP395 is an orally available macrolide or ‘Barriolide’ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for […]